TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
TRxADE Health, Inc. (NASDAQ: MEDS) has announced a significant corporate change. The company, along with its wholly owned subsidiary Scienture, , will be rebranding as Scienture Holdings, Inc. effective Monday, September 23, 2024. This transformation extends to the stock market, where the company will begin trading under the new ticker symbol NASDAQ:SCNX on the same date.
This name change represents a strategic shift for the company, potentially aligning its corporate identity more closely with its subsidiary's operations. The move could signal a new direction or focus for the business, though specific reasons for the change were not provided in the announcement.
TRxADE Health, Inc. (NASDAQ: MEDS) ha annunciato un importante cambiamento aziendale. L'azienda, insieme alla sua controllata interamente posseduta Scienture, si rifarà il brand come Scienture Holdings, Inc. a partire da lunedì 23 settembre 2024. Questa trasformazione si estende anche al mercato azionario, dove l'azienda inizierà a quotarsi con il nuovo simbolo di borsa NASDAQ:SCNX nello stesso giorno.
Questo cambiamento di nome rappresenta una variazione strategica per l'azienda, allineando potenzialmente la sua identità corporativa alle operazioni della sua controllata. La mossa potrebbe segnalare una nuova direzione o focus per l'attività, anche se nell'annuncio non sono state fornite ragioni specifiche per il cambiamento.
TRxADE Health, Inc. (NASDAQ: MEDS) ha anunciado un cambio corporativo significativo. La compañía, junto con su subsidiaria de propiedad absoluta Scienture, se cambiará de nombre a Scienture Holdings, Inc. a partir del lunes 23 de septiembre de 2024. Esta transformación también se extiende al mercado de valores, donde la compañía comenzará a cotizar bajo el nuevo símbolo bursátil NASDAQ:SCNX en la misma fecha.
Este cambio de nombre representa un giro estratégico para la empresa, alineando potencialmente su identidad corporativa más cerca de las operaciones de su subsidiaria. El movimiento podría señalar una nueva dirección o enfoque para el negocio, aunque en el anuncio no se proporcionaron razones específicas para el cambio.
TRxADE Health, Inc. (NASDAQ: MEDS)가 중요한 기업 변화를 발표했습니다. 이 회사는 전액 자회사인 Scienture와 함께 Scienture Holdings, Inc.로 브랜드 변경을 할 예정이며, 이는 2024년 9월 23일 월요일부터 시행됩니다. 이 변화는 주식 시장에도 적용되며, 회사는 동일한 날짜에 새로운 티커 기호 NASDAQ:SCNX으로 거래를 시작할 것입니다.
이 이름 변경은 회사의 전략적 전환을 의미하며, 자회사 운영과 더 밀접하게 회사의 정체성을 맞추는 것을 목표로 합니다. 이 움직임은 사업의 새로운 방향이나 초점을 알릴 수 있지만, 변화의 구체적인 이유는 발표에서 제공되지 않았습니다.
TRxADE Health, Inc. (NASDAQ: MEDS) a annoncé un changement d'entreprise significatif. La société, avec sa filiale entièrement détenue Scienture, sera rebaptisée Scienture Holdings, Inc. à compter du lundi 23 septembre 2024. Cette transformation s'étend également au marché boursier, où la société commencera à être cotée sous le nouveau symbole NASDAQ:SCNX à la même date.
Ce changement de nom représente un tournant stratégique pour l'entreprise, potentiellement en alignant son identité d'entreprise plus étroitement avec les opérations de sa filiale. Ce mouvement pourrait signaler une nouvelle direction ou un nouvel objectif pour l'entreprise, bien que des raisons spécifiques pour ce changement n'aient pas été fournies dans l'annonce.
TRxADE Health, Inc. (NASDAQ: MEDS) hat eine bedeutende Unternehmensänderung angekündigt. Das Unternehmen wird zusammen mit seiner hundertprozentigen Tochtergesellschaft Scienture ab Montag, den 23. September 2024, als Scienture Holdings, Inc. umbenannt. Diese Transformation erstreckt sich auch auf den Aktienmarkt, wo das Unternehmen am selben Tag unter dem neuen Börsenkürzel NASDAQ:SCNX gehandelt wird.
Diese Namensänderung stellt einen strategischen Wandel für das Unternehmen dar und könnte die Unternehmensidentität enger mit den Geschäften seiner Tochtergesellschaft verknüpfen. Dieser Schritt könnte eine neue Richtung oder Fokussierung für das Geschäft signalisieren, obwohl im Ankündigung keine konkreten Gründe für die Änderung genannt wurden.
- Rebranding may indicate a strategic shift or new business focus
- Continued listing on NASDAQ exchange
- None.
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. (“Scienture Holdings”), effective Monday, September 23, 2024. Scienture Holdings stock will begin trading under the new ticker symbol NASDAQ:SCNX on September 23, 2024.
About TRxADE
TRxADE HEALTH, INC. historically focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. Our current primary operations are conducted through our wholly-owned subsidiary, Integra Pharma Solutions, LLC (“IPS”), which is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products to customers. IPS customers include all healthcare markets including government organizations, hospitals, clinics and independent pharmacies nationwide.
About Scienture
Scienture, LLC is a NY based branded, specialty pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Scienture recently entered into a business combination with TRxADE Health, Inc. (NASDAQ: MEDS) in an all-stock transaction valued at
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. TRxADE undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
TRxADE
TRxADE HEALTH, INC.
6308 Benjamin Rd, Suite 708
Tampa, Florida 33634
Phone: (866) 468-6535
Email: IR@Rxintegra.com
FAQ
When will TRxADE Health (MEDS) change its name to Scienture Holdings?
What will be the new stock ticker for Scienture Holdings (formerly MEDS)?
Is Scienture, related to the TRxADE Health (MEDS) name change?
